5.	INVENTORIES

Inventories consist of the following as of:

(in thousands)	June 30, 2015		December 31, 2014
Raw materials	$	9,945	$	5,056
Packaging materials		922		794
Work-in-progress		350		411
Finished goods		1,763		1,368
		12,980		7,629
Reserve for excess/obsolete inventories		(279)		(111)
Inventories, net	$	12,701	$	7,518

Vendor Concentration

We source the raw materials for our products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon our current vendors to reliably supply the API required for ongoing product manufacturing. During the three months ended June 30, 2015, we purchased approximately 43% of our inventory from two suppliers. During the six months ended June 30, 2015, we purchased approximately 40% of our inventory from the same two suppliers. As of June 30, 2015, amounts payable to these suppliers was immaterial. During the three months ended June 30, 2014, we purchased approximately 34% of our inventory from two suppliers. During the six months ended June 30, 2014, we purchased approximately 40% of our inventory from the same two suppliers.